Eurofins to buy Bio-Access – will Biomnis be next?

As forecast here, Eurofins Scientific is to enter the European medical diagnostic lab sector with the acquisition of Bio-Access. But the deal has little rationale, unless Eurofins also buys French reference lab Biomnis.

Apax enters race for Synlab

Rothschild and BC Partners have infuriated private equity bidders for Synlabs by allowing Apax-owned Unilabs to enter the bidding for the Pan-European lab group.

FREE BLOG Who really makes money out of labs?

Blaise Mentha, Jean-Louis Oger, Eric Souetre - it is striking how charismatic entrepreneurs serially trouser millions from diagnostic labs. It is much harder for private equity to make money from lab groups. Why? And does the same hold true for other healthcare sectors?

Report: Spain: Europe’s fertility playground

In Spain, the fertility market is booming as patients from near and far flock to clinics and fork out cash for a chance at happiness. Clinica Tambre, a medium sized private clinic in the centre of Madrid, claims that 40% of its patients come from nearby France and Italy for treatment. The driving force behind this is egg cell donation.

Brazil’s largest homecare group Dal Ben to increase volumes with HMOs

Dal Ben, which claims to be Brazil’s largest homecare company, aims to diversify its client base through partnerships with Health Maintenance Organisations (HMOs), as well as expanding into nursing homes and acute hospitals. We speak to Marcelo Fonseca, board member of Dal Ben, about the future of homecare in Brazil.

Hassab Labs looks to catch up with IDH

Egypt’s third largest lab group, Hassab Labs, is targeting North Africa as it ramps up its expansion plans. CEO Mohamed Azab says a partnership with the pan-African, Saham Insurance, will provide opportunities there and across the rest of the continent. But is it too late?

NMC pays nearly $1.8m per bed for ProVita

NMC Health, the UAE’s second largest hospital and outpatient group, has acquired ventilator-dependent, long-term care group ProVita for an enterprise value (EV) of $160.6m in cash. With ProVita currently only having 90 beds, this deal values each bed at close to $1.8m, emphasising the shortage and demand for long-term care in the region.